Curant Health

HIV Pipeline Prospects Getting HealthierThere is no cure for HIV, but with proper medical treatment, the disease can be controlled.
Opinion: Top 2 takeaways from Asembia Specialty Pharmacy SummitThe conference raised important points about value-based contracts and the specialty pharmacy space.
Clinical team alignment top priority for payersInvestment in resources that support clinicians and patients closer to the point of care may be the cure for what ails managed care executives.
Value-based care takes over J.P. Morgan Healthcare Conference 2017Is the drive to value-based care really accelerating? What can be done amidst all of the uncertainty? Expert shares insights from the J.P. Morgan 35th Annual Healthcare Conference.
Four things to know about the 21st Century Cures ActThe 21st Century Cures Act, a landmark medical research bill, offers healthcare executives a promising future.
What billions in lost pharma revenue means for managed carePharmaceutical manufacturer relationships and next-gen value based contracts are primed to accelerate value-derivation from your drug spend.
Three ways to rein in drug costs regardless of who becomes presidentIt’s time for stakeholders to cooperate in order to limit the wasted spending on prescription medications and chart a path to collectively improving value derivation.
Medication adherence: High tech still needs a personal touchWhere do the capabilities of healthcare technology end and the need for the human hand begin to deliver top value for managed care executives?
How your pharmacy partners impact your Star RatingsAre you tracking your prospective pharmacy partners to measure their potential impact on your Star Rating? You should be.
Real-world results determine value-based price for specialty drugsIn an era when adherence to specialty pharmaceuticals is disturbingly low, value-based pricing needs real-world results, not single-arm accelerated trials.